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Cannabis through the looking glass: chemo- and
enantio-selective separation of phytocannabinoids
by enantioselective ultra high performance
supercritical fluid chromatography†
G. Mazzoccanti, a O. H. Ismail, a I. D’Acquarica, *a C. Villani, a C. Manzo,b
M. Wilcox,c A. Cavazzini d and F. Gasparrini *a
By using the Inverted Chirality Columns Approach (ICCA) we have
developed an enantioselective UHPSFC method to determine the
enantiomeric excess (ee) of ()-D9-THC in medicinal marijuana
(Bedrocans). The ee was high (99.73%), but the concentration of
the (+)-enantiomer (0.135%) was not negligible, and it is worth a
systematic evaluation of bioactivity.
Cannabinoids are one of the constituents of marijuana, the
crude drug derived from the plant Cannabis sativa L. The term
phytocannabinoids has been coined just to emphasize their
plant-derived origin1 with respect to synthetic cannabinoids
(e.g., nabilone,2a dexanabinol,2b or ajulemic acid2c) and endogenous
cannabinoid receptor ligands (namely, endocannabinoids).3 The
most abundant and psychologically active compound of the class is
()-D9-trans-tetrahydrocannabinol (D9-trans-THC),4,5 which has
indeed been the subject of thousands of papers.6,7 Furthermore,
we are currently witnessing a remarkable breakthrough in
the recreational use of cannabis, with respect to the mode of
consumption, short-term effects, chronic health consequences
and cannabis use disorders.8
Another fascinating feature of phytocannabinoids is that most
of them are chiral, and are produced, in the plant, in a single-
enantiomer format, as typically occurs for natural products,
with some exceptions.9 As a result, restricted stereochemical
requirements are present for the interaction of cannabinoids
with the cannabinoid (CB) receptors,10 and this has led numerous
groups to investigate the possibility of separating the undesirable
psychotropic effects from the desirable effects by suitable changes
in stereochemistry. For example, the ()-enantiomer of the
synthetic cannabinoid dexanabinol (HU-210) is one of the most
potent psychotropically active cannabinoids known, while the
corresponding (+)-enantiomer (i.e., HU-211) is devoid of the
THC-like psychotropic effects.11 It becomes evident, therefore,
the importance of the stereochemical efficiency of synthetic
pathways to unnatural cannabinoid analogues, as well as the
efficiency of the determination of the enantiomeric purity
(namely, enantiomeric excess, ee) in naturally occurring samples,
in both single and in more complex mixtures.
We became interested in investigating the composition of
Cannabis plant extracts from a stereochemical point of view; in
fact, while stringent rules have been established by the FDA for
the content determination of THC and cannabidiol (CBD) in
medicinal marijuana,12 the stereochemical features of such
molecules and the determination of the enantiomeric purity
have not yet been put into the foreground by the agency.
Furthermore, although the point of the chromatographic
resolution of chiral cannabinoids13a has already been raised in
1993 and more recently addressed for synthetic cannabinoids,13b
analytical approaches to crude plant extracts have been developed
by just taking into account the single cannabinoids, irrespective
of their stereochemistry.14
We started the investigation by focusing our attention on the
phytocannabinoids collected in Fig. 1. Apart from the typical
three-letter acronyms,4,5 we included a bold number for each
molecular entity, for the sake of clarity in the identification of the
enantiomerically correlated molecules. In fact, it is well known
that all the naturally occurring cannabinoids exist in the single-
enantiomer format, i.e., the (R,R)-form, which displays a negative
optical rotation and a trans-configuration at the cyclohexene
ring. Nevertheless, we have designed, for each structure, its mirror
image (i.e., the unnatural dextrorotatory enantiomer) to get a full
idea of any implicit stereochemical scenario in cannabinoids.15
Cannabidivarin (CBDV, 1) and cannabidiol (2), which feature two
chiral centres, belong to the CBD-type subgroup of cannabinoids,4
the only difference between them being the length of the alkyl
side chain at C30 (propyl and pentyl, respectively). From the
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THC-type subgroup of cannabinoids,4 we extracted both the
D8-THC-type (3) and the D9-THC-type (4) cannabinoids, which
are double-bond position isomers of THC, the former being less
psychologically potent than the latter. Another fascinating
chiral phytocannabinoid is cannabichromene (CBC, 5), that
presents only one chiral centre, and it is typically reported as a
rare case of a natural racemate.4,5 This cannabinoid has no
psychotropic effect, but interesting pharmacological activities
such as anti-inflammatory, antifungal and antimicrobial pro-
perties have been reported.16 We have included, in the inves-
tigation, also two achiral cannabinoids, i.e., cannabigerol
(CBG, 6), which is the biosynthetic precursor of CBC, and
cannabinol (CBN, 7), whose concentration in Cannabis products
(i.e., marijuana, hashish and hash oil) has been shown to
increase during the storage of these materials. Thus, it was
necessary to develop an analytical method, which had to be
enantio- and chemo-selective at the same time.
The first problem we faced in stereoselective analysis of
Cannabis plant extracts was that vegetable extracts are highly
enriched complex mixtures and often the minor enantiomers,
or the racemates, are not available as reference samples. To
overcome this limitation, our group has previously developed a
method for the identification and accurate quantification of the
minor enantiomer in trace analysis of natural products, named
the ‘‘Inverted Chirality Columns Approach’’ (ICCA).17a,b
This method is based on the switching between two Chiral
Stationary Phases (CSPs) having the same bound selector with
an opposite configuration, to reverse the elution order of a
given enantiomeric pair, according to the reciprocal principle
of selectand–selector-systems.17c This technique is very useful
when the minor enantiomer follows the major one and it is
partially hidden by the tailing of the leading enantiomer: on the
CSP with opposite configuration the trace enantiomer is eluted
first, thus enabling a more precise and accurate quantification
by peak area integration.
Pirkle-type CSPs (such as the DACH-DNB and the Whelk-O1)
are the ideal instruments for the application of the ICCA approach,
because they exist in both the enantiomeric versions.17a,b From
2010, a clear trend towards the development of CSPs in the
sub-2 mm format has been reported for the chromatographic
separation of chiral analytes to enhance both analysis speed and
column efficiency.18 This has opened new frontiers in the field of
enantioselective ‘‘e’’ Ultra-High Performance Liquid Chromato-
graphy (eUHPLC)19 and enantioselective ‘‘e’’ Ultra-High Performance
Supercritical Fluid Chromatography (eUHPSFC).20 SFC has indeed
recently undergone an outstanding revival in the enantio-
separation of pharmaceuticals, particularly in the initial screening
stage of the drug discovery process.21
In this work, we successfully applied, for the chemo- and
enantio-selective separation of phytocannabinoids, the ICCA
method using, as the inverted chirality columns, those based
on the (S,S)- and (R,R)-Whelk-O1 CSPs in the sub-2 mm format,
under eUHPSFC conditions. It must be acknowledged that
UHPSFC technology proved recently to be an alternative and ortho-
gonal solution for the separation of synthetic cannabinoids.13b,14
The two UHPC-Whelk-O1 sub-2 mm CSPs were prepared
according to a previously described procedure19c starting from
Kromasil 1.8 mm silica particles, and slurry packed into 100 
4.6 mm I.D. stainless steel columns. To evaluate the separation
ability of the Whelk-O1 CSP towards different cannabinoids, a
mixture containing seven standards (i.e., ()-1, ()-2, ()-3,
()-4, ()-5, 6 and 7, whose structures are shown in Fig. 1)
was prepared starting from the commercially available stock
solutions (0.1–1.0 mg ml1) in methanol. All the standards have
been well separated within 12 minutes using CO2/MeOH, 98 : 2
as the mobile phase, at a flow-rate of 3.5 ml min1, under
isocratic and isoconfertic conditions (see Fig. S1 of the ESI†).
This result was taken as a proof of the optimal chemoselectivity
of the Whelk-O1 CSP, in particular for the couple D8-THC (3)
and D9-THC (4), which are simply two positional isomers.
Fig. 1 Chemical structures of the main naturally occurring chiral phytocannabinoids and of their mirror images. The picture also includes two achiral
cannabinoids, namely CBG (6) and CBN (7).
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The analysis of a further standard mixture obtained by repla-
cing the ()-4 standard with the corresponding commercially
available racemate (i.e., ()-4) has provided evidence of the
enantioselective capability of the phase towards ‘‘THC’’ as well,
the (+)-enantiomer eluting before the naturally occurring ()-4
on the (S,S)-Whelk-O1 column. Furthermore, the column proved
to be capable of separating the two enantiomers of CBC
(compound 5), which was added to the mixture of standards
as the racemate, and whose absolute configuration at C30 has
not yet been determined.4 The identification of the two CBC
enantiomers was made by checking their elution order in the
(R,R)-Whelk-O1 column under standard HPLC conditions (see
Fig. S2 of the ESI†) and simultaneous UV and CD detection at
280 nm (the first eluting enantiomer is the negative peak).
Afterwards, the two UHPC-Whelk-O1 sub-2 mm columns
were tested in order to check their full equivalence, both from
a chemical (i.e., retention and selectivity) and a geometrical
(i.e., packing efficiency) point of view, as required by the ICCA
method.17a For this purpose, a six-component standard mixture
was analyzed for both the (S,S)- and (R,R)-Whelk-O1 columns
under the same UHPSFC conditions (see Fig. 2), and we could
confirm that just the enantiomerically correlated peaks have
been inverted by switching from one column to the other,
whereas the achiral molecules (i.e., 6 and 7) were not affected
by the variation, and eluted from the two columns with identical
retention behaviours (see Table S1 of the ESI†).
By applying the ICCA protocol to the above-mentioned
standard mixture, we were able to simulate a virtual racemate
for those compounds that were available just as single enantiomers
(i.e., ()-1 and ()-2). The simulation (see dot lines in Fig. 2) has
allowed us to predict the retention factor (k0), the enantio-
selectivity (a) and the resolution (Rs) for the virtual ()-1/(+)-1 and
()-2/(+)-2 couples (see Table S1 of the ESI†).
As a final investigation, we analyzed an ethanol extract from
Bedrocans (medicinal marijuana from Cannabis sativa L. strains)
which is claimed to contain ‘‘THC’’ as the major component
(Fig. 3). Indeed, by expanding the chromatogram baseline, we
have detected, besides ‘‘THC’’, also ‘‘CBC’’, ‘‘CBG’’ and ‘‘CBN’’
in smaller amounts (see Table S2 of the ESI†), together with a
chiral unknown impurity. Moreover, thanks to the ICCA
method, we made it possible to elute the minor enantiomeric
impurity (+)-4 before the major one (i.e., ()-4) and thus we
were able to measure an ee equal to 99.73% on the UHPC-(S,S)-
Whelk-O1 column (see Table 1). Notably, for ‘‘CBC’’, we found
that, instead of being a racemate, the ee is about 25% (equally
measurable on both the columns), which means that it occurs
as a scalemic mixture.
We can conclude that the chromatographic system we have
developed proved useful in the chemo- and enantio-selective
separation of all the tested cannabinoid samples, and it has been
demonstrated to be reliable for the determination of extreme ee
of D9-THC in pharmaceutical formulations. Notably, it is the first
time that the trace (+)-enantiomer of ‘‘THC’’ has been quantified
in medicinal marijuana. Such a feature is fundamental both for
further evaluation of the bioactivity and in the case of single-
molecule cannabinoid pharmaceutical products (e.g., Marinols),
whose stereochemistry must be accurately controlled.
We thank financial support from Sapienza Universita` di
Roma, Italy (Funds for Selected Research Topics 2017–2018).
Fig. 2 Demonstration of the chemical equivalence of the two 1.8 mm
UHPC-(R,R)- and (S,S)-Whelk-O1 columns (100  4.6 mm I.D.) upon
separation of a six-component cannabinoid standard mixture. The dotted
lines represent the (+)-enantiomers of compounds 1 and 2 predicted by the
ICCA method. Mobile phase: CO2/MeOH = 98 : 2; flow-rate: 3.5 ml min
1;
T = 30 1C; ABPR = 1500 psi; detection: UV at 214 nm. For the chemical
structures of 1–7, see Fig. 1.
Fig. 3 A Bedrocans ethanol extract analyzed by applying the ICCA
protocol. For peak identification, the chromatogram of a six-component
cannabinoid standard mixture has been shown in the inset as a dotted line
trace. The asterisk denotes a chiral unknown impurity.
Table 1 Determination of the enantiomeric excess (ee) for ‘‘THC’’ (4)
and CBC (5) in the Bedrocans ethanol extract on the UHPC-Whelk-O1
sub-2 mm columns under eUHPSFC conditions
CSP config. Peak name Area (mV s) EFa (%) ee (%)
(R,R) ()-4 3 694 825 —b —b
(+)-4 —b —b
(S,S) (+)-4 4917 0.135 99.73
()-4 3 642 648 99.865
(R,R) [CD()280]-5c 18 766 37.42 25.16
[CD(+)280]-5c 31 383 62.58
(S,S) [CD(+)280]-5c 31 346 62.81 25.62
[CD()280]-5c 18 559 37.19
a EF = enantiomeric fraction. b On the (R,R)-Whelk-O1 column the (+)-4
peak is eluting on the tailing of the major ()-4 component and thus it
is not quantifiable. c Plus and minus signs refer to the signs of the
circular dichroism (CD) band at the indicated wavelength.
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